Koers Onconova Therapeutics Inc Nasdaq
Aandelen
US68232V1089
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 210K 194K | Omzet 2025 * | 300K 277K | Marktkapitalisatie | 12,75 mln. 11,75 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,2 mln. | Nettowinst (verlies) 2025 * | -28 mln. -25,81 mln. | EV/omzet 2024 * | 60,7 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 42,5 x |
K/w-verhouding 2024 * |
-0,7
x | K/w-verhouding 2025 * |
-0,73
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 85,39% |
Recentste transcriptie over Onconova Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 19-01-15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 01-09-13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 24-10-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 01-07-15 |
Jack Stover
BRD | Director/Board Member | 69 | 23-05-16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 01-04-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+54,05% | 58,71 mld. | |
-2,02% | 41,31 mld. | |
+40,01% | 39,2 mld. | |
-10,22% | 27,4 mld. | |
+13,42% | 26,55 mld. | |
-21,60% | 18,98 mld. | |
+2,89% | 12,51 mld. | |
+22,40% | 11,94 mld. | |
+27,49% | 12,08 mld. |